The latest list of the world's top 1,000 pharmaceutical companies!

Behind the exclusive 249 of the world's top 1,000 pharmaceutical companies in China is the general trend that the value of the global pharmaceutical industry is gradually shifting from the United States, Switzerland and other places to China and other Asian regions
.

Among the TOP100 global pharmaceutical companies, the traditional pharmaceutical giants represented by Hengrui, CSPC, and Qilu are forming a stormtrooper to take the lead in winning the "new drug war", and the emerging teams represented by Baekje and Cinda are also advancing by leaps and bounds.

In 2012, the global investment bank Torreya began to conduct research on 30,000 pharmaceutical companies worldwide
.

In 2021, the agency published the "Report on the Top 1000 Pharmaceutical Companies in the World", which ranked 1,000 pharmaceutical companies by valuation.

According to the agency's estimates, the total value of the global pharmaceutical industry today is 7.
03 trillion US dollars, a year-on-year increase of 5.
6%
.

This report found six major changes:

First, in the past 14 months, large pharmaceutical companies have maintained their share of total market value, while the share of market value of companies headquartered in China or Biotech has increased
.

In contrast, brand-name pharmaceuticals have shrunk slightly, and brand-name generic drugs have lost nearly half of their value share

Second, the transfer of pharmaceutical technology from small molecules to biologics has slowed down
.

The market share of companies focusing on small molecules was 58.

Third, the top five countries in the global pharmaceutical industry are the United States, China, Switzerland, the United Kingdom and Germany.
China has entered the second echelon of the global pharmaceutical industry, growing from a market share of 6.
5% in 2015 to a market share of 14.
4% in 2020
.

However, due to the centralized procurement policy, the price of generic drugs fell sharply, causing China's global market share to decline by 2.

Fourth, the geographical distribution of the biotechnology field is showing a trend of rapid diversification
.

The data shows that the value share of the top nine regions in the global biotechnology ranking has fallen from 71% 14 months ago to 54% today, and the non-popular regions of the United States and China are gaining most of the new shares

Fifth, from the perspective of the therapeutic field, 39% of the market's value is related to new tumor treatments, and the value of rare diseases and neurology companies accounts for 23%
.

Sixth, the report studied the role of private equity in commercial pharmaceuticals and found that 13% of the world's largest commercial pharmaceutical companies have private equity/financial sponsored investors
.

It is worth mentioning that there are 249 Chinese pharmaceutical companies (including Hong Kong, Macao and Taiwan) among the top 1,000 pharmaceutical companies this year, compared with about 208 last year
.

How did these pharmaceutical companies perform this year?

Part of the list is only the top 100 (for the complete list, please reply back to "Top Thousand Pharmaceutical Companies")

01.
Big Pharma's general downfall, Hengrui, CSPC, and Qilu take the lead in fighting the new drug "war"

01.
Big Pharma's general downfall, Hengrui, CSPC, and Qilu take the lead in fighting the new drug "war"

Compared with 2020, the world's TOP5 players and rankings have changed drastically
.

Although Pfizer divested Huizhi, it still regained its supremacy with the new crown vaccine (estimated sales of $36 billion in 2021)
.

In addition to the valuation increase brought by the new crown vaccine, there are also new crown drugs.

Roche abdicated third in the rapid rise of Pfizer and AbbVie
.

Take the third quarter's financial report for example, Roche's year-on-year growth was only 5%, while AbbVie reached 11%
.

Two diabetes drug companies Novo Nordisk and Eli Lilly hit the top 5 in market value
.
In one year, Novo Nordisk's market value ranking rose from 10th to 4th in the world, and its stock value increased by US$102 billion; while Eli Lilly's market value ranking rose from 11th to 5th
.
Take Novo Nordisk as an example.
Its total revenue in the first three quarters of 2021 increased by 13% year-on-year to DKK 10.
467 billion, and its profit increased by 12% year-on-year.
The main business of diabetes and obesity care was calculated in DKK for the first three quarters.
A year-on-year increase of 10%
.

The original market value of "Thanhua" Novartis has been declining, ranking 3rd in 2018, dropping to 6th in 2020, and ranking 9th this year
.
The market value reflects the comprehensive expectations of investors.
Although Novartis has many new products, the lack of blockbuster drugs has been criticized by the outside world
.

Back in China, traditional Big Pharma has generally performed poorly in the capital market this year, including Hengrui Pharmaceuticals, China Biopharmaceuticals, Hansen Pharmaceuticals (Hausen Pharmaceuticals), Kelun Pharmaceuticals, etc.
, all have declined to varying degrees, with only a few Several Big Pharmas are on the rise, such as CSPC, Qilu Pharmaceutical, and Fosun Pharma
.

This status quo is inevitable, and there is no need to panic
.
Currently, this batch of Big Pharma is at different stages of the transformation process to innovative drugs, and some have gone further on the road of innovation.
Innovative drugs can make up for the pressure brought by the price cuts of some generic drugs.
Hengrui is a good example; Some have just embarked on the road of innovation, and are more affected by policies, and the market value changes more, such as Yangtze River Pharmaceutical
.
But overall, this is a good thing
.

"There is no war without bloodshed", the new drug war that China is unfolding needs
.

Hausen Pharmaceuticals is a Big Pharma that has changed a lot in its market value ranking this year, dropping from 33rd last year to 82nd this year
.
However, from the perspective of the financial report, the sales revenue of innovative drugs in the first half of the year of Hausen Pharmaceuticals accounted for 28.
5%, an increase of 66.
8% year-on-year, and the company's overall revenue growth rate was only 10.
6% during the same period
.
Its new products (fast-follower) are on the market in batches.
In 2019, polyethylene glycol loxenatide, ametinib in 2020, and imitinofovir in 2021 are all marketed as category 1 innovative drugs, and Striving to enter the medical insurance that year, this new drug strategy can be called a "throttling" strategy-focusing resources on innovative research and development, to a certain extent, represents the determination of the "Houses" to transform and innovate
.

On the other hand is the "open source" strategy, that is, the introduction of products to quickly supplement the pipeline, but the use of this tool needs to consider the current situation of the company, such as supplementing mature products to quickly bring sales, or supplementing more innovative early pipelines, or Cooperate on technology platforms
.
Also take Hausen as an example.
In October, it intensively deployed the field of small nucleic acids, through the platform of its partner Silence Therapeutics, to cooperate in the development of 3 target SiRNAs, and through OliX Pharmaceuticals' GalNAc-asiRNA platform for liver-related drug development
.

China Biopharmaceuticals, Kelun Pharmaceutical, CSPC, and Qilu all have the same principle, but they are also slightly different
.
For example, Qilu is the enterprise with the largest collection of varieties every time.
Will he not get hurt? The answer is "definitely", but Qilu's products are large in volume, and the cost can be lower than most companies relying on economies of scale, and the sales of the first generic drug can be quickly achieved by relying on years of business experience
.

Fosun Pharma is also a different example
.
Relying on Fosun Group, the company is born to be good at capital operation, and most of its ways to participate in innovation are through incubation of innovation or investment
.
This strength of Fosun has been fully utilized during the epidemic.
It was the first to find a BioNTech cooperation mRNA vaccine, even before Pfizer.
This product has brought Fosun 1.
5 billion yuan in revenue in the first three quarters (Hong Kong, Macau and Taiwan)
.
The market value of this cooperation has increased even more, from a market value of tens of billions to a market value of hundreds of billions
.
Of course, Fosun Kate, which it incubated, has an impact.
Fosun Kate has launched the first domestic CAR-T product-Akilunza injection
.

02.
Baekje and Cinda advance by leaps and bounds, leading Biotech to the height of innovation

02.
Baekje and Cinda advance by leaps and bounds, leading Biotech to the height of innovation

When will China be able to give birth to a world-class innovative pharmaceutical company? Don't worry, the seeded player has been born
.

Among the top 100 Chinese bio-innovative pharmaceutical companies this time, BeiGene and Cinda Biotech are undoubtedly the most promising representatives
.

BeiGene's market value ranking has risen from 52 in 2020 to 38th this year, once again achieving a leap forward
.
Cinda Bio will rank 90th in 2020, and this year it will continue to rise to 77th
.

There are joys and worries
.
Junshi Biology’s performance was the most eye-catching in the list last year.
It jumped from 265 in 2019 to 94.
It clings to Xinda Biology.
However, Junshi Biology’s ranking dropped abruptly in this year’s list and dropped to the TOP100 list.
In the 146th place
.

Unlike Hengrui, CSPC, and Qilu, Baekje were born to be innovative drugs
.
They are not dragged down by mature products (generic drugs), and there is basically no obstacle to financing.
They are surrounded by well-known capital and they have enough funds to invest in R&D.
For example, Baekje is known as the "new brother of R&D investment
.
" At the same time, Baekje is also good at rapidly expanding pipelines through cooperation, and the favorable conditions of the time and place make them a sweet pastry for the "new talent market
.
" In short, all favorable conditions are allowing them to lead domestic pharmaceutical companies to the forefront of innovation
.

2020 coincides with the tenth anniversary of the founding of BeiGene.
In the first ten years, BeiGene has been shining brightly.
As the beginning of the new decade, the latest financial report shows that BeiGene's total revenue in the first three quarters of 2021 will reach 962.
3 million US dollars.
, An increase of 361% over the same period last year, of which product revenue was approximately US$440 million, with equal emphasis on external authorization and product sales
.

In terms of products, since the BTK inhibitor Zebutinib was first approved in the United States in 2019, it has now been approved in 10 countries around the world.
This is China's first new drug commercialized globally
.
The latest financial report shows that the global sales of Zebutinib in the third quarter of 2021 were US$65.
8 million, an increase of 320% year-on-year, while domestic sales also increased by 223% year-on-year
.

In January this year, Baekje and Novartis reached a US$2.
2 billion PD-1 development and commercialization cooperation agreement.
The US$650 million advance payment once broke the previous record and is also a promoter of its market value increase
.

In addition to the products on the market, BeiGene continued to publish its product pipeline and R&D layout in August, showing that BeiGene has more than 50 preclinical projects underway, covering areas ranging from double antibodies/triple antibodies, ADC, PROTAC to mRNA, CAR-NK can be said to have everything.
According to reports, 11 self-developed drugs have entered the clinical or commercialization stage
.

Just today (November 16), the China Securities Regulatory Commission issued an announcement stating that it agreed to the registration of BeiGene's initial public offering on the Science and Technology Innovation Board in accordance with legal procedures
.
The birth of the world's first biotechnology company listed on the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange has entered the final countdown
.

As we all know, commercialization is the key to the transformation of Baekje, so the commercialization capability will inevitably become a wing to the innovation highland
.

And Cinda Bio, which has always insisted on building its own commercialization team, is the most successful representative of the first batch of commercialized Biotech
.
Its PD-1 sales in the third quarter of this year are about 800 million yuan, which is about the total amount of Baiji and Junshi.
This commercialization capability also allows Cinda to attract some domestic Biotech
.
For example, Yasheng Pharmaceutical has cooperated in the development and commercialization of multiple products such as its blockbuster new drugs HQP1351 (the first domestic third-generation BCR-ABL inhibitor) and APG-2575 (the domestic potential first Bcl-2 inhibitor)
.
At that time, Yang Dajun, the founder of Yasheng Pharmaceutical, admitted the reason for the cooperation: while building a sales team by itself, it is the best choice to choose a company with a strong commercialization team for sales
.
Another example is the cooperation with Baoyuan Pharmaceutical, which is a manifestation of Cinda's commercialization strength
.

03.
Pien Tze Huang rises to 16 places in a row, and the market value of Ameike surpasses Yunnan Baiyao

03.
Pien Tze Huang rises to 16 places in a row, and the market value of Ameike surpasses Yunnan Baiyao

In general, the ranking of Chinese medicine companies has slightly improved among global pharmaceutical companies
.
Among the top 100 pharmaceutical companies, the finalists are still Zhangzhou Pien Tze Huang Pharmaceutical and Yunnan Baiyao
.

Zhangzhou Pien Tze Huang Pharmaceutical ranked 33rd this year, up 16 places compared to last year
.
As of press date, its market value is approximately US$43.
1 billion
.
According to its financial report for the third quarter of 2021, the company's revenue from January to September 2021 was approximately US$950 million, a year-on-year increase of 20.
55%; the net profit attributable to shareholders of listed companies was approximately US$310 million, a year-on-year increase of 51.
36%
.

In June of this year, Pien Tze Huang attracted attention due to the price rise again.
Pien Tze Huang, which was "1000 yuan per pill", was hailed as "Moutai in medicine"
.
The performance growth in the first three quarters also shows that although the price of a single product is increasing, it does not affect its sales
.

In contrast, Yunnan Baiyao's performance is slightly inferior, ranking 71st
.
Its performance this year was not as good as last year's, and it dropped 12 places in the ranking
.
As of press date, its market value is approximately $18.
3 billion
.
Its financial report for the third quarter of 2021 shows that the company's revenue from January to September 2021 is approximately US$4.
43 billion, an increase of 18.
52% year-on-year; the net profit attributable to shareholders of listed companies is approximately US$375 million, a year-on-year decrease of 42.
38%
.

It can be seen that Yunnan Baiyao's revenue in the first three quarters has maintained growth but profits have dropped a lot, mainly due to the increase in the company's floating losses in stocks
.
The quarterly report shows that in the first three quarters, the gains and losses from changes in the fair value of Yunnan Baiyao's trading financial assets during the holding period were RMB 1.
555 billion
.

Wind data shows that in the first three quarters of 2021, the total operating income of CITIC Chinese Medicine Production Index sector companies was 276.
124 billion yuan, a year-on-year increase of 9.
17%, and the total net profit was 26.
846 billion yuan, a year-on-year increase of 42.
65%.
After the epidemic, the performance of the Chinese medicine sector was significantly restored
.

The "Moutai among women", also at the Maotai level, Amic also appeared in the list of the top 100 pharmaceutical companies, ranking 54th
.
As of press date, its market value is about 19.
9 billion U.
S.
dollars, which has surpassed Yunnan Baiyao and ranked among the 100 billion market value
.

Amicco’s 2021 third-quarter financial report shows that the company’s revenue from January to September 2021 is approximately US$160 million, a year-on-year increase of 120.
29%; the net profit attributable to shareholders of listed companies is approximately US$110 million, a year-on-year increase of 144.
09%
.

Can a group of hyaluronic acid hold up a market value of 100 billion yuan? Judging from the current figures, it has been supported
.

The medical beauty industry itself has the dual attributes of medical treatment and consumption, which also makes its market potential have a lot of room for imagination
.
With the improvement of economic conditions and the improvement of living standards, the public's demand for beauty has also continued to increase, and the medical beauty market has also continued to expand
.
Sullivan's "2020 Global and China Hyaluronic Acid (HA) Industry Market Research Report" shows that China has become the world's third largest medical beauty market, with a market size of 143.
6 billion yuan in 2020 and 318.
5 billion yuan in 2024 Yuan
.

Among them, hyaluronic acid is still the most widely used material in medical aesthetic projects, and it is favored by the market
.
The report shows that the market size of China's medical and cosmetic hyaluronic acid terminal products in 2020 is still larger than other medical-grade terminal applications, reaching 5.
77 billion yuan, ranking first, and is expected to reach 147.
1 in 2025 with a compound growth rate of 20.
6%.
100 million yuan
.
The increase in market penetration of major products has also brought good results for Amic
.